Legislative, Regulatory & Legal

The use of pharmacy DIR fees has increased by 45,000% between 2010 and 2017, per a letter from Rep. Cathy McMorris Rodgers, R-Wash., to Health and Human Services secretary Alex Azar.

The Food and Drug Administration issued a proposed rule that would update regulatory requirements for most sunscreen products currently on the market in the United States.

Indivior is introducing an authorized generic of its own Suboxone, in anticipation of generic competition from Dr. Reddy's and Alvogen.

On the heels of a favorable U.S. Court of Appeals ruling, Dr. Reddy's is relaunching its generic Suboxone sublingual film

The Food and Drug Administration’s new pathway for Competitive Generic Therapies affords companies early benefits, including meetings with regulators.

With the Food and Drug Administration approving record numbers of generics, manufacturers are positioning their companies for success in the new environment.

A record number of pharmacy advocates will keep the issue of DIR fee reform on the front burner at NACDS RxIMPACT day.

In comments to the House Ways and Means committee, the National Association of Chain Drug Stores pointed out that DIR fee reform can reduce patients’ out-of-pocket drug costs and overall healthcare spending,